BrightSpring Health Services (BTSG) has entered Q1 2026 earnings season after a busy 2025, with Q4 revenue at about US$3.6b and basic EPS of US$0.24 anchoring the latest reported quarter. The company reported quarterly revenue moving from US$2.6b in Q3 2024 to US$3.6b in Q4 2025, while basic EPS shifted from a US$0.13 loss per share in Q3 2024 to a positive US$0.24. This sets up a results season where the focus is on how those headline gains relate to margins and the quality of recurring profit.

See our full analysis for BrightSpring Health Services.

With the Q4 numbers reported, the next step is to see how this profit and revenue profile aligns with the widely followed growth and risk narratives around BrightSpring and where those narratives might need updating.

Q4 2025 revenue climbs to US$3.6b alongside improving net income

• Across 2025, BrightSpring reported quarterly revenue moving from US$2.9b in Q1 2025 to US$3.6b in Q4 2025, while net income excluding extra items moved from US$9.7m in Q1 2025 to US$49.3m in Q4 2025, showing a very different profit profile to the loss of US$24.9m in Q3 2024.
• Consensus narrative argues that leadership in specialty pharmacy and rare drug markets supports long term earnings growth, and the recent shift from a trailing loss of US$66.5m in Q4 2024 to trailing net income of US$106.3m in Q4 2025 gives that view some backing, although reliance on government reimbursement and higher labor costs in the same narrative are still clear pressure points for future margins.
  • Trailing twelve month revenue rose from about US$10.1b in Q4 2024 to US$12.9b in Q4 2025, which lines up with the idea of a larger addressable market in home and community based care, but also makes the business more sensitive to any reimbursement changes mentioned in the consensus risks.
  • At the same time, analysts are assuming margins rise from 0.4% to 2.2% by 2028, yet the interest coverage risk flagged in the analysis means investors still need to watch how much of the growing profit pool is absorbed by financing costs.

Twelve month EPS of US$0.53 versus 101x P/E

• On a trailing basis BrightSpring earned basic EPS of US$0.53 with net income of US$106.3m, which when set against the current share price of US$52.58 implies a P/E of about 101x compared with peer and industry averages around 25x.
• Bulls point to forecast earnings growth of about 25% per year and revenue growth of roughly 13.3% per year as the reason a high P/E can be justified, yet the fact that interest payments are not well covered by earnings directly challenges the bullish idea that profit expansion alone will quickly make this valuation multiple look modest.
  • The bullish narrative talks about earnings potentially reaching hundreds of millions of US dollars, but the most recent trailing net income is US$106.3m, so the company still has to grow several times from here before those scenarios line up with today’s price.
  • With the shares at US$52.58 relative to a single allowed analyst price target of US$54.21, the gap is much smaller than the difference to the DCF fair value of about US$146.27, which means the market is currently siding more with cautious or middle of the road expectations than with the most optimistic growth path.

On days when the growth story and the valuation seem hard to reconcile, it can help to see how bullish investors connect the dots between specialty pharmacy momentum, margin expansion, and those higher long term earnings targets, then decide how much of that you actually buy into. 🐂 BrightSpring Health Services Bull Case

DCF fair value far above price, but debt risk stands out

• The shares trade at US$52.58 compared with a DCF fair value estimate of about US$146.27, which is a discount of roughly 64%, while interest coverage remains weak enough that interest payments are described as not well covered by earnings.
• Bears focus on that leverage, highlighting net debt of about US$2.5b and a leverage ratio of 3.6x in their narrative, and the current P/E of roughly 101x together with thin trailing earnings of US$106.3m gives some weight to the concern that higher financing costs or slower profit growth could limit how quickly equity holders benefit from the large gap to DCF fair value.
  • Consensus expectations of revenue growth at around 10.1% to 13.3% per year and margin expansion from low single digits require continued investment in staff, technology, and integration, all of which can be harder to fund if a bigger slice of operating profit is diverted to interest.
  • The fact that trailing EPS is only US$0.53 while the company carries several billions of US dollars in annual revenue underlines how small the current profit margin is, which is exactly the kind of thin buffer that cautious investors flag when debt and interest coverage are front and center.

If you are weighing that big discount to DCF fair value against the pressure from debt and interest costs, it is worth seeing how the more skeptical market view frames those same numbers and what profit path they think is realistic. 🐻 BrightSpring Health Services Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for BrightSpring Health Services on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

The mix of optimism and concern is clear, so it makes sense to move quickly, review the underlying numbers yourself, and weigh both sides of the story using the 3 key rewards and 1 important warning sign

See What Else Is Out There

BrightSpring's thin profit margins, high P/E of about 101x, and leverage with weak interest coverage indicate that balance sheet risk is a key concern.

If that level of debt and interest pressure feels uncomfortable, you may wish to shift your attention to companies with stronger cushions by checking out the solid balance sheet and fundamentals stocks screener (45 results)

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.